Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMANTADINE HYDROCHLORIDE vs APOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.
Prophylaxis and treatment of influenza A virus infection,Treatment of Parkinson's disease and drug-induced extrapyramidal symptoms
Traditional use for respiratory conditions (e.g., asthma, bronchitis) in homeopathy; not FDA-approved for any indication.
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
10 mg orally once daily, with or without food.
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Terminal half-life 3.5 hours; dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism, with no major cytochrome P450 involvement.
Metabolized via oxidative dimerization by peroxidases (e.g., myeloperoxidase, horseradish peroxidase); not extensively studied in humans.
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Renal: 90% unchanged; fecal: 10% as metabolites.
Approximately 67% bound to plasma proteins (mainly albumin).
95% primarily to albumin.
3-10 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, erythrocytes).
0.5 L/kg; indicates moderate tissue distribution.
Oral bioavailability: 86-90% after immediate-release formulation; steady-state achieved within 4-7 days.
Oral: 60% (first-pass metabolism).
Cr Cl 30-50 m L/min: 200 mg on day 1, then 100 mg once daily. Cr Cl 15-29 m L/min: 200 mg on day 1, then 100 mg every other day. Cr Cl <15 m L/min or on hemodialysis: 200 mg every 7 days. Adjust based on clinical response and tolerability.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: reduce to 5 mg once daily; e GFR <15 m L/min: not recommended.
No specific dosage adjustment required in hepatic impairment, but use with caution due to potential central nervous system effects.
Child-Pugh A (mild): no adjustment; Child-Pugh B (moderate): reduce to 5 mg once daily; Child-Pugh C (severe): not recommended.
Influenza A treatment/prophylaxis: children 1-9 years: 4.4-8.8 mg/kg/day (max 150 mg/day) in 1-2 divided doses; 9-12 years: 100 mg twice daily; ≥12 years: adult dosing. Not routinely recommended due to widespread resistance.
Not indicated for patients under 18 years of age.
Initiate at 100 mg once daily or lower, considering age-related decline in renal function; titrate slowly with careful monitoring for adverse CNS effects.
Initiate at 5 mg once daily; titrate based on response and tolerability; monitor renal function.
None
No FDA black box warnings; not FDA-approved.
Risk of suicidality, especially in patients with a history of psychiatric disorders,May exacerbate seizure disorder; use with caution in epilepsy,Can cause orthostatic hypotension, dizziness, and blurred vision, impairing ability to drive or operate machinery,Neuroleptic malignant syndrome (NMS) has been reported with dose reduction or discontinuation,Renal function impairment requires dose adjustment; accumulation can cause toxicity,Elderly patients are more susceptible to CNS effects
May cause allergic reactions in sensitive individuals.,Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to potential hemolysis.,Not evaluated for safety during pregnancy or lactation.
Hypersensitivity to amantadine or any component of the formulation,Severe uncontrolled psychiatric disorder (relative)
Known hypersensitivity to Apocynum or related plants.,G6PD deficiency (theoretical risk)
Avoid alcohol and caffeine; alcohol may increase CNS depression, caffeine may exacerbate insomnia and nervousness. No specific food restrictions.
Avoid high-protein meals close to dosing as may reduce absorption; take on empty stomach or as directed.
First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second and third trimesters: No controlled data; case reports of preeclampsia, premature labor, and fetal distress with use near term. FDA Pregnancy Category C.
Apogen is not a recognized drug name. Assuming Apogen refers to an aminoglycoside antibiotic (e.g., gentamicin), pregnancy category D: Risk of fetal harm. First trimester: Potential for ototoxicity and nephrotoxicity, but data limited. Second and third trimesters: Risk of fetal cranial nerve VIII damage and renal impairment. Avoid use unless life-threatening infection with no safer alternative.
Amantadine is excreted into breast milk; milk-to-plasma ratio (M/P) approximately 0.7-1.0 (based on single case, M/P 1.0 at 200 mg/day). Infant serum concentrations up to 6% of maternal therapeutic levels reported. Potential for anticholinergic effects and extrapyramidal symptoms in nursing infant. AAP recommends caution; weight benefits vs. risks.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.3-0.5). Limited oral bioavailability reduces infant exposure, but theoretical risk of gut flora alteration and mucosal damage. Use with caution, monitor infant for diarrhea, candidiasis, or allergic reactions.
Pregnancy increases renal clearance (by 20-50% in second/third trimester) due to increased glomerular filtration rate. For Parkinson's disease or influenza A, consider starting at lower dose (100 mg daily) and titrate upward as needed, monitoring for efficacy and CNS side effects. No standard dose adjustment guidelines; individualize based on therapeutic response and tolerance.
Increased volume of distribution and glomerular filtration rate in pregnancy may lower peak serum concentrations. Dose based on ideal body weight and renal function. Monitor serum levels; adjust to achieve therapeutic peaks and troughs. Postpartum: Return to prepregnancy dosing.
For Parkinson's disease, start at 100 mg twice daily; increase gradually to 100 mg TID or QID if needed. In elderly or renal impairment, reduce dose. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for orthostatic hypotension, livedo reticularis, and peripheral edema. Can worsen psychosis in patients with dementia. For influenza A, start within 48 hours of symptoms; not a substitute for vaccination. Use with caution in patients with seizure disorders or heart failure.
APOGEN (apomorphine sublingual) is used for 'on-off' episodes in Parkinson's disease. Administer under tongue; do not swallow. Onset ~15-30 min. Monitor for hypotension, nausea (use antiemetic like domperidone pre-treatment). Avoid with 5-HT3 antagonists (e.g., ondansetron). QT prolongation risk.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Avoid alcohol as it may increase side effects like dizziness.,Notify your doctor if you experience swelling in your legs or ankles, a lacy purple skin rash, or confusion.,If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up.,Wear sunscreen and protective clothing; amantadine may make your skin more sensitive to sunlight.,Do not take this medicine for influenza unless directed by a doctor; it is not a substitute for the flu vaccine.
Place tablet under tongue and allow to dissolve completely; do not chew or swallow.,Do not eat or drink until tablet fully dissolves.,Take exactly as prescribed for 'off' episodes.,Common side effects include nausea, dizziness, and drowsiness.,Avoid alcohol and other CNS depressants.,Rise slowly from sitting or lying to prevent falls.,Report prolonged erections or fainting immediately.
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMANTADINE HYDROCHLORIDE vs APOGEN, answered by our medical review team.
AMANTADINE HYDROCHLORIDE is a Antiviral / Antiparkinsonian that works by Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.. APOGEN is a Antiviral that works by Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMANTADINE HYDROCHLORIDE and APOGEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMANTADINE HYDROCHLORIDE is: For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.. The standard adult dose of APOGEN is: 10 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMANTADINE HYDROCHLORIDE and APOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMANTADINE HYDROCHLORIDE is classified as Category C. First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second . APOGEN is classified as Category C. Apogen is not a recognized drug name. Assuming Apogen refers to an aminoglycoside antibiotic (e.g., gentamicin), pregnancy category D: Risk of fetal harm. First trimester: Potentia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.